All In Biotech

Drug Trial Radar · NCT01677689

Study to Investigate the Efficacy and Safety of Apomivir®

A Prospective, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Apomivir® in Relieving Influenza Symptoms

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

May 31, 2026

Primary completion

May 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Far East Bio-Tec Co., LtdIndustry
Sponsor type
Industry
First posted
Sep 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.

Conditions

  • Influenza

Interventions

  • Apomivir®Drug

    Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

  • PlaceboDrug

    Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety profile of Apomivir® treatment (120 mg b.i.d.).Time frame: from day1 to day 29, the entire treatment period and follow-up period.
  2. To evaluate the time to resolution of influenza symptoms defined as all flu symptom scores ≤ 1 after initiation of study treatment.Time frame: from day 1 to day 29, depends on the time to sympton resolution of individual subjects.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Medical University Hospital

    Taichung, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.